|Publication number||US3880995 A|
|Publication date||Apr 29, 1975|
|Filing date||May 14, 1973|
|Priority date||May 14, 1973|
|Publication number||US 3880995 A, US 3880995A, US-A-3880995, US3880995 A, US3880995A|
|Inventors||Jones E Linn|
|Original Assignee||Lilly Co Eli|
|Export Citation||BiBTeX, EndNote, RefMan|
|Referenced by (44), Classifications (9)|
|External Links: USPTO, USPTO Assignment, Espacenet|
United States Patent Jones Apr. 29, 1975 TREATMENT OF ARTHRITIS WITH  Field of Search 424/180; 260/210, 343.2 R
MYCOPIIENOLIC ACID AND DERIVATIVES  Inventor: E. Linn Jones, Indianapolis, Ind. Primary ExamInerQEIbert Roberts Attorney, Agent, or FzrmJames L. Rowe; Everet F.  Assrgnee: Eli Lilly and Company, Indianapolis, S i h Ind.
 Filed: May 14, 1973  ABSTRACT  A N 360,292 Mycophenolic acid or its glucuronide is administered to patients suffering from inflammatory arthritis for th ll 'tfth th 't t 52 us. Cl 424/180; 260/210; 260/343.2 R e a em o ar Symp 0m  lm. Cl. A01N 9/00 4 Claims, N0 Drawings TREATMENT OF ARTHRITIS WITH MYCOPIIENOLIC ACID AND DERIVATIVES BACKGROUND OF THE INVENTION Mycophenolic acid is known to exhibit antifungal, antiviral and antibacterial activity. [See for example, J. Gen. Virol. 4, 629 (1969); J. Antibiotics 22, 297 (1969).]
Inflammatory arthritis is a fairly common problem 5 M h nolic acid fl-D-glucuronide is described by usually attacking the older segment of the pop l ion Ando et a]. in J. Antibiotics, 23, 408 (1970) and its analthough extremely severe cases of inflammatory arti-tumor activity is set forth in that same article. thritis are found, through infrequently, in younger per- It is an object of this invention to provide anew drug SOHS- for the treatment of arthritis and for the alleviation of lnflammatory arthritis may be classified into two 1() arthritic symptoms which is devoid ofcertain ofthe del based on the Presence of absence of a Serum ficiencies of other drugs employed in the past for these rheumatoid factor. The sero-positive group includes purposes rheumatoid arthritis and arthritis associated with connective tissue or collagen disease including systemic SUMMARY OF THE INVENTION lupus erythematosus and polyarteritis (periarteritis no- I f lfill f h above d other bj hi i The Seromegatlve group includes p' vention provides a method of treating inflammatory arthritis, ankylosing spondylitis and arthritis associated h i i comprising administering to a human suffering with ulcerative colitis, regional ileitis and Whipples h efrom an arthritic symptom relieving amount of a disease. Other forms of arthritis such as degenerative compound of the formula 9 joint disease (osteoarthritis) and arthritis caused by wherein M is hydrogen, potassium, sodium or ammometabolic or endocrine disorders, are also seronegative but are not classified with inflammatory arthritis. [For a discussion and classification of arthritis, see for example Harrisons Principles of lnternal Medicine, Ed. Wintrobe et al., 6th Edition (McGraw-Hill Book Co., New, NY. 1970) Section 13, particularly pages -l Inflammatory arthritis, generally, and rheumatoid and psoriatic arthritis in particular have been subject to more or less successful drug therapy for a number of years, the most acceptable of the drug treatments being either gold therapy or the use of the anti-inflammatory drugs aspirin, indomethacin and butazolidine. Neither of these treatment methods are free from defects. Gold therapy and aspirin administration are not uniformly successful and the two more recently introduced antiinflammatory drugs, indomethacin and butazolidine, are frequently toxic at therapeutic levels, usually necessitating a dose reduction, if not outright withdrawal, of the drug followed by a return of the arthritic symptoms. Other drug therapy of arthritis, such as the hormonal approach employing corticoids, has fallen into relative disuse, either for failure to alleviate the symptoms to the degree thought desirable or because of the extreme severity of the side effects accompanying their administration.
Mycophenolic acid is produced by various strains of fungi of th'e Penicillium brevicompactum, Penicillium stolomferum and Penicillium urtic/zae groups. The com; 60
pound was the first biologically-active compound iso-' lated from a mold. The initial isolation was carried out by Gosio in 1896 (Gosio, Rivista d lgiene e Sanita pubblica, Ann., 7 825, 869, 961 ). Structure work was effected largely through the efforts of Raistrick et a]. from 1932 to 1935 (Raistrick et al., Biochem. .I. 26, 1441 ; Biochem J. 27, 654 ).
nium and R is hydrogen or B-D-glucuronidyl COOH When M is hydrogen and R is hydrogen, the above compound is named systematically as 6-[4-hydroxy-7- methyl-6-methoxy-3-oxo-5-phthalanyl]-4-methyl-4- hexenoic acid or mycophenolic acid. When R is B-D- glucuronidyl and M is hydrogen, the resulting compound is mycophenolic acid B-D-glucuronide or, systematically, 6-[ 4-( ,B-D-glucopyranosylglucuronate )-4- methyl-6-methoxy-3-oxo-5-phthalanyl]-4-methyl-4- hexenoic acid. Other non-toxic salts than those listed above can also be employed.
Mycophenolic acid, mycophenolic acid B-D- glucuronide or salts thereof are administered by the oral route to a human suffering from inflammatory arthritis, such as rheumatoid or psoriatic arthritis. For oral use, mycophenolic acid, its B-D-glucuronide, or salts thereof are administered in the form of tablets or capsules or as a liquid solution or suspension. A preferred mode for oral administration is via telescoping gelatin capsules. A typical useful formulation employing capsules is prepared as follows:
9.4 kg. of mycophenolic acid isolated from a fermentation medium is thoroughly mixed with 4.7 kg. of starch and the mixture loaded into empty telescoping gelatin capsules. Each capsule contains the following ingredients 400 mg. mycophenolic acid 200 mg. starch In the above formulation, mycophenolic acid [3-D- glucuronide, prepared by the method of Ando et al. (supra) can be substituted for mycophenolic acid.
In the above formulation it has been stated that it is preferred to employ the drug in the form of the free acid; however, the sodium, potassium or ammonium l salts are also effective. Formulations employed for the salts are substantially the same as those indicated above for the free acid.
In carrying out my novel treatment method, patients diagnosed as suffering from inflammatory arthritis are treated with from 2 to 5 g. of mycophenolic acid or an equivalent amount of its glucuronide or of a salt thereof per day. The daily dosage should be divided into either 2 or 3 doses.
An example of the use of the treatment method of this invention is as follows: A male subject 22 years old who had been diagnosed as suffering from psoriatic arthritis two years previously was found to have the following joints involved in his arthritis: shoulders, hips, right wrist, right hand, proximal interphalangial joints of third and fourth fingers and distal interphalangial joint of the thumb. The rheumatoid factor was negative indicating that the disease involved was psoriatic arthritis. Mycophenolic acid was administered to the patient at the rate of 1200 to 2400 mg every 12 hours over a 6 week period. Improvement was noticed at the end of 3 weeks as follows: The patient mentioned that there was improved comfort, decreased morning stiffness and he no longer needed to take aspirin.
A second, female patient of 46 years was diagnosed as suffering from psoriatic arthritis with hips, left wrist, and sacroiliac involved. She was given from 800 to 1600 mg of mycophenolic acid every eight hours for a 12-week period. Subjective improvement was noticed at the end of one week with the following comments: There was less pain in wrist and hips, less swelling of wrists (an objective improvement) and increased range of rotation. Again, in this instance, the need for aspirin was eliminated.
Mycophenolic acid B-glucuronide as well as cationic salts of mycophenolic acid can be employed in the treatment of inflammatory arthritis at dose levels equivalent to those specified above for mycophenolic acid itself. By equivalent dose levels is meant the same weight of mycophenolic acid per dose.
I. The process of treating inflammatory arthritis in humans which comprises administering by the oral route to a human suffering therefrom an arthritis symptom relieving amount of mycophenolic acid or a derivative thereof represented by the following formula UNITED STATES PATENT AND TRADEMARK OFFICE CETHICATE OF CORRECTION PATENT N0. 5,880,995
DATED April 29, 1975 INVENTOR(S) E Linn Jones It is certified that error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown below:
Column 1, line 8, "through" should read --though--,
Column 4, line 36, delete "[or B-D-glucuron1dyl].".
' Signed and Scaled this eighth Day of June 1976 ismu Arrest:
|Citing Patent||Filing date||Publication date||Applicant||Title|
|US4327074 *||Feb 12, 1979||Apr 27, 1982||Adolf W. Schwimmer||Method for diagnosis and selective treatment of infections of bacteria having β-glucuronidase activity|
|US4584368 *||Oct 13, 1978||Apr 22, 1986||Adolf W. Schwimmer||β-Glucuronidase activity and/or pH-dependent pharmaceuticals and thier methods of production|
|US4686234 *||Nov 27, 1985||Aug 11, 1987||Syntex (U.S.A) Inc.||Mycophenolic acid derivatives in the treatment of inflammatory diseases, in particular rheumatoid arthritis|
|US4725622 *||Jan 23, 1986||Feb 16, 1988||Syntex (U.S.A.) Inc.||Mycophenolic acid derivatives in the treatment of rheumatoid arthritis|
|US4808592 *||Sep 4, 1987||Feb 28, 1989||Syntex (U.S.A.) Inc.||Method of treating diseases by administering morpholinoethylester of mycophenolic acid and derivatives thereof|
|US4868153 *||Aug 17, 1988||Sep 19, 1989||Syntex (U.S.A.) Inc.||Treatment of allograft rejection with mycophenolic acid, its morpholinoethylester and derivatives thereof|
|US4948793 *||Jun 29, 1989||Aug 14, 1990||Syntex (U.S.A.) Inc.||Treatment of autoimmune diseases with the morpholinoethyl ester of mycophenolic acid, and derivatives thereof|
|US4952579 *||Nov 14, 1988||Aug 28, 1990||Syntex (U.S.A.) Inc.||Method of treating diseases by administering morpholino-ethylester of mycophenolic acid or derivatives thereof|
|US4959387 *||Nov 24, 1987||Sep 25, 1990||Syntex (U.S.A.) Inc.||Mycophenolic acid derivatives in the treatment of rheumatoid arthritis|
|US4992467 *||Mar 28, 1990||Feb 12, 1991||Syntex (U.S.A.) Inc.||Treatment of autoimmune diseases with mycophenolic acid, and derivatives and formulations thereof|
|US5177072 *||Dec 9, 1991||Jan 5, 1993||Syntex (U.S.A.) Inc.||Treatment of autoimmune inflammatory, and psoriatic diseases with heterocyclic aminoalkyl esters of mycophenolic acid and derivatives|
|US5283257 *||Jul 10, 1992||Feb 1, 1994||The Board Of Trustees Of The Leland Stanford Junior University||Method of treating hyperproliferative vascular disease|
|US5346997 *||Aug 26, 1992||Sep 13, 1994||Murphy James G||Agents for complexing sodium under biological conditions|
|US5472707 *||May 9, 1994||Dec 5, 1995||Syntex (U.S.A.) Inc.||High dose ranolazine formulations|
|US5688529 *||Mar 29, 1995||Nov 18, 1997||Syntex (U.S.A) Inc.||Mycophenolate mofetil high dose oral suspensions|
|US6025391 *||Apr 10, 1997||Feb 15, 2000||Novartis Ag||Enteric-coated pharmaceutical compositions of mycophenolate|
|US6172107||Dec 22, 1999||Jan 9, 2001||Novartis Ag||Entric-coated pharmaceutical compositions|
|US6306900||Oct 23, 2000||Oct 23, 2001||Novartis Ag||Enteric coated pharmaceutical compositions|
|US6471980||Feb 13, 2001||Oct 29, 2002||Avantec Vascular Corporation||Intravascular delivery of mycophenolic acid|
|US6858221||Sep 11, 2002||Feb 22, 2005||Avantec Vascular Corporation||Intravascular delivery of mycophenolic acid|
|US7077859||Dec 14, 2001||Jul 18, 2006||Avantec Vascular Corporation||Apparatus and methods for variably controlled substance delivery from implanted prostheses|
|US7083642||Jul 25, 2002||Aug 1, 2006||Avantec Vascular Corporation||Delivery of therapeutic capable agents|
|US7615535||Dec 29, 2006||Nov 10, 2009||Duke University||Inhibiting GS-FDH to modulate no bioactivity|
|US8217006||Sep 24, 2009||Jul 10, 2012||Duke University||Inhibiting GS-FDH to modulate no bioactivity|
|US20030139801 *||Jul 25, 2002||Jul 24, 2003||Avantec Vascular Corporation||Delivery of therapeutic capable agents|
|US20040127435 *||Aug 1, 2003||Jul 1, 2004||Regents Of The University Of California||Uses for inhibitors of inosine monophosphate dehydrogenase|
|US20050013859 *||Oct 16, 2002||Jan 20, 2005||Dederichs Juergen||Pharmaceutical compositions comprising mycophenolic acid or mycophenolate salt|
|US20050107869 *||Dec 9, 2004||May 19, 2005||Avantec Vascular Corporation||Apparatus and methods for controlled substance delivery from implanted prostheses|
|US20050125054 *||Nov 19, 2004||Jun 9, 2005||Avantec Vascular Corporation||Devices delivering therapeutic agents and methods regarding the same|
|US20050131532 *||Dec 10, 2004||Jun 16, 2005||Avantec Vascular Corporation||Apparatus and methods for controlled substance delivery from implanted prostheses|
|US20050203612 *||Jun 27, 2003||Sep 15, 2005||Avantec Vascular Corporation||Devices delivering therapeutic agents and methods regarding the same|
|US20060106453 *||Dec 13, 2005||May 18, 2006||Avantec Vascular Corporation||Delivery of therapeutic capable agents|
|US20060212109 *||May 19, 2006||Sep 21, 2006||Avantec Vascular Corporation||Delivery of therapeutic capable agents|
|US20070032483 *||Sep 10, 2004||Feb 8, 2007||Julia Greil||Process for the production of mycophenolate mofetil|
|US20070111949 *||Dec 29, 2006||May 17, 2007||Duke University||Inhibiting GS-FDH to modulate no bioactivity|
|US20100010082 *||Jul 9, 2009||Jan 14, 2010||Aspreva International Ltd.||Formulations for treating eye disorders|
|US20100015121 *||Sep 24, 2009||Jan 21, 2010||Duke University||Inhibiting gs-fdh to modulate no bioactivity|
|US20100210717 *||May 3, 2010||Aug 19, 2010||Dederichs Juergen||Pharmaceutical compositions comprising mycophenolic acid or mycophenolate salt|
|EP1349562A2 *||Dec 14, 2001||Oct 8, 2003||Duke University||Inhibiting gs-fdh to modulate no bioactivity|
|EP1349562A4 *||Dec 14, 2001||Aug 6, 2008||Univ Duke||Inhibiting gs-fdh to modulate no bioactivity|
|EP1475091A1 *||Sep 27, 1994||Nov 10, 2004||Roche Palo Alto LLC||Mycophenolate mofetil - high dose oral suspensions|
|WO1980000791A1 *||Oct 2, 1979||May 1, 1980||Schwimmer A||B-glucuronidase activity and/or ph-dependent pharmaceuticals and their methods of production and use for selective treatment of diseases|
|WO1994001105A1 *||Jul 7, 1993||Jan 20, 1994||The Board Of Trustees Of The Leland Stanford Junior University||Method of treating hyperproliferative vascular disease|
|WO1995009626A1 *||Sep 27, 1994||Apr 13, 1995||Syntex (U.S.A.) Inc.||Mycophenolate mofetil high dose oral suspensions|
|U.S. Classification||514/27, 549/310, 536/18.1, 514/456|
|Cooperative Classification||A61K31/34, A61K31/70|
|European Classification||A61K31/34, A61K31/70|